IBC Meeting Minutes Cleveland Clinic Florida Research and Innovation Center

Date:		Location:						
July 17 th , 2025		Zoom						
IBC Member Attendance:								
☑ McDonald, Christine (IBC Chair)	⊠ Li, K	un	⊠ Such, Kimberly					
□ Champer, Dylan (BSO)	⊠ Hajja	r, Adeline	☐ Judd, Leslie					
⊠ Tavakoli, Sara	⊠ O'Co	nnor, Christine	□ Doud, Melissa					
Guests: Amanda Dragan*, Abby Bifano*, Anthony Santilli*, Jennifer Veillette*, Nikki Meyer* *Cleveland Clinic Main Campus								
Call To Order:		Adjourn:						
2:30 pm		3:02 pm						
		·	·					

I. Review of June 9th, 2025 Meeting Minutes

Committee Comments: None			
Motion:	For:	Against:	Abstain:
Approval	8	0	1

II. Review of July 17th , 2025 Meeting Minutes

Committee Comments:			
None			
Motion:	For:	Against:	Abstain:
Approval	8	0	1

III. Administrative Business

a. Committee presented with personnel additions.

IV. Non-Clinical Research:

a. Renewals:

Basic Research	Protocol ID:	PI:	Biosafety Level:	NIH Cat.:
Renewal # 1	FLIBC013	Choi	BSL-2	III-D-1-a, III-D-3-a

Project Titles: Lentivirus production and trantarget genes.		n expressio	n, knockdov	wn, and kno	ockout of	
Associated Grant Numbers: NIH: R01-AI171201-01, Non						
• Generation of replication cells; Human derived		ral particle	s, transduct	ion of tissu	e culture	
Function/Nature of Recombin ☐ N/A ☐ Oncogene ☐ Tumo ☐ Immunomodulatory ☐ Toxin	r Suppressor Gene	Structural Structural	•	•	microbial	
Species of Recombinant Gene □ N/A ⊠ Human □ Murine	-	□ Viral	⊠ Other			
Risk Assessment Discussion: ⊠ Yes □ No	:		Facilities, Procedures, and Safety Practices Reviewed (Y/N):			
Discussion/Required ModifiAdministrative edits	cations:					
PI/Supervisor Training (Y/N ⊠ Yes □ No	V):	Handler 🖂 Yes	Training (Y/N):		
Motion: Approved with Administrative Revisions	For: 8	Against:	Abstain:	Recuse:	Not Present:	
1	1		<u> </u>			

b. Amendments:

	Protocol ID:	PI:	Biosafety Level:	NIH Cat.:					
	FLIBC001	Gack	BSL-1, BSL-2,	III-F-1, III-F-2, III-					
Basic Research			BSL-2+, ABSL-2	F-3, III-F-8, III-D-					
Amendment # 1				1-a, III-D-2-a, III-					
				D-3-a, III-D-4-b,					
				III-D-7, III-E					
Project Titles:									
Regulation of Host Antiviral Innate Immunity									
Associated Grant N	Associated Grant Numbers:								

NIH (2023): 5DP1AI169444-03, 5R01 AI148534-04, 5R01 AI165502-03, 5 R37 AI087846- 14, 1 R21 AI174534-01A1; Non-NIH Funding								
Summary of Approved Items: Propagation of recombinant and non-recombinant viruses, transduction of tissue culture cells, administration of viruses and viral transduced cells <i>in vivo</i> ; Generation and propagation of recombinant and wild type SARS-CoV-2 virus, infection of cell lines and experimental analyses, administration of recombinant and wild type SARS-CoV-2 virus <i>in vivo</i> ; Humanderived materials.								
Requested Addition		_						
Addition of no	ew flav	ivirus no	nstructu	ral pr	oteins to l	oe expressed	l in cells	
Function/Nature of Recombinant Genes to be Expressed: □ N/A □ Oncogene □ Tumor Suppressor Gene □ Structural □ Signaling □ Antimicrobial □ Immunomodulatory □ Toxin □ Antibiotic Resistance □ Reporters ☑ Other Species of Recombinant Genes to be Expressed: □ N/A □ Human □ Murine □ Rat □ Bacterial ☑ Viral □ Other								
Risk Assessment Dis	scussion	1:			Facilitie	s, Procedui	res, and Sa	afety
⊠ Yes □ No						es Reviewed	l (Y/N):	
Discussion/Required	l Modi	fications	•		⊠ Yes	□ No		
None None	i Wiour	ilcations	•					
PI/Supervisor Train	ing (Y/	N):			Handlei	Training (Y/N):	
⊠ Yes □ No				1	⊠ Yes	□ No		1
Motion: Approval		Fo 8		A	gainst: 0	Abstain:	Recuse:	Not Present:
Basic Research	Proto	col ID:	PI:		Biosaf	ety Level:	NI	H Cat.:
Amendment # 2	FLIE	3C017	Li		BSL-3	3, ABSL-3	III-D-1-	-b, III-D-4-b
Project Titles: Host-pathogen interactions during Coronavirus infection								
Associated Grant Numbers:								
Non-NIH Funding Summary of Approved Items:								
Acquisition and Prop	agation	of WT a						
MERS, infection of tissue culture cells, administrations <i>in vivo</i> ; Human derived materials.								

Requested Additions	/Chan	ges:						
Adding compo		_	nent in bo	oth in	vitro and	in vivo stu	dies and ad	lministration
routes								
Function/Nature of Re								
						_	_	timicrobial
☐ Immunomodulatory		n □An	tibiotic R	esista	nce \square Re	porters \square C	Other	
G : CD 1:		4 1	г	1				
Species of Recombina ⊠ N/A □ Human □			•		□ Viral [7 Other		
Risk Assessment Dise			⊔ Васте	riai			una and Ca	· Catr
XISK ASSESSMENT DISC ✓ Yes	cussioi	1:				s, Procedu es Reviewed	*	nety
△ res □ No					☐ Yes	S Reviewed	1 (1/14).	
Discussion/Required	Modif	fications	ı•					
Administrative		iications	•					
• Contingent Ite								
_		eview of	safety pr	oced	ures for de	escribed adı	ministration	n routes
o spanis		.,10,,, 01	sorresy pr					
PI/Supervisor Traini	ing (Y/	N):			Handler	· Training (Y/N):	
⊠ Yes □ No	Ο,	ŕ			⊠ Yes	□ No	•	
Motion:								Not
Approved with		Fo	r:	A	gainst:	Abstain:	Recuse:	Present:
Contingency		8	3		0	1	0	0
								Ů
D 1 D 1	Proto	col ID:	PI:		Biosaf	ety Level:	NI	H Cat.:
Basic Research	FLIE	3C019	Ross	S		, BSL-2+,		III-E
Amendment # 3					AI	BSL-2		
Project Titles:								
Influenza virus neutra								
Associated Grant Nu	ımbers	S:						
Non-NIH Funding								
Summary of Approv			1	ď	4 0 D	. 1	TD 1	
Propagation and generations and generations							s; Transauc	ction of
tissue culture cells; ad			vivo; nu	man-	uerivea iii	lateriais.		
Requested AdditionsAddition of no		_	2 0					
Addition of its	cw viia	ıı subtyp	CS					
Function/Nature of Re	ecombi	nant Gei	nes to be	Expr	essed:			
Function/Nature of Recombinant Genes to be Expressed: ⊠ N/A □ Oncogene □ Tumor Suppressor Gene □ Structural □ Signaling □ Antimicrobial								
☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Other								
	10/11					r		
Species of Recombina								
-	ant Gen	nes to be	Expresse	ed:				
⊠ N/A □ Human □ Murine □ Rat □ Bacterial □ Viral □ Other								

Risk Assessment Discussion:					Facilities, Procedures, and Safety					
⊠ Yes □ No					Practices Reviewed (Y/N):					
					⊠ Yes	⊠ Yes □ No				
Discussion/Required		fications	:							
Administrativ	e edits									
PI/Supervisor Train	ing (Y	/N):			Handler	· Training ((Y/N):			
⊠ Yes □ No					⊠ Yes	□ No				
Motion:								Not		
Approved with		Fo		A	gainst:	Abstain:	Recuse:	Present:		
Administrative Revis	ions	8	3		0	1	0	0		
Basic Research	Proto	col ID:	PI:		Biosaf	ety Level:	NI	H Cat.:		
Amendment # 4	FLI	BC025	Ros	S		, BSL-2+,	III-F-1,	III-F-2, III-		
					Al	BSL-2		E-1		
Project Titles:					. ~					
Utilizing novel mRN	A vacc	ines to pr	otect aga	aınst	ınfluenza	intection				
Associated Grant N	umhar	g•								
Non-NIH Funding	umbei	3.								
Summary of Approv	ved Ite	ms:								
Propagation and gene			binant Ir	ıfluer	nza A & B	viral protei	ns; Transd	uction of		
tissue culture cells; g						-				
administration of mR	NA an	d influenz	za partic	les to	mice and	ferrets; hur	nan-derive	d materials.		
Requested Addition	s/Chan	iges:								
Addition of n	iew vira	al subtype	es							
Function/Nature of R										
						_	ū	timicrobial		
☐ Immunomodulatory	☐ Tox	in \square An	tibiotic R	esista	ince \square Re	porters \square (Other			
G · CD 1:		. 1	Г	1						
Species of Recombin			-		□ 3 7' 1 □	7.04				
⊠ N/A □ Human □	」 Murin	ie 🗆 Kat	□ Bacte	eriai	⊔ Viral L	□ Otner				
Risk Assessment Dis	cussio	n:			Facilitie	s. Procedu	res, and Sa	afety		
Risk Assessment Discussion: Facilities, Procedures, and Safety ✓ Yes ☐ No Practices Reviewed (Y/N):										
					⊠ Yes	□ No	, ,			
Discussion/Required	d Modi	fications	:							
Administrativ	e edits									
DI/C · T	• 47	/N.T.\			77 11	TD	(X / / / X I)			
PI/Supervisor Train	ing (Y	/N):				Training ((Y/N):			
⊠ Yes □ No					⊠ Yes	□ No				

Motion:	_			1	Not
Approved with	For:	Against:	Abstain:	Recuse:	Present:
Administrative Revisions	8	0	1	0	o o
					0

				1						
	Protocol ID:	PI:		Biosaf	ety Level:	NI	H Cat.:			
Basic Research	FLIBC026	Ross	5	BSL-1	1, BSL-2,	III-F-8,	III-F-2, III-			
Amendment # 5				BSL-2	+, BSL-3,	F-3, III	-D-7, III-E,			
					2, ABSL-3	I)	II-E-1			
Project Titles:										
H2 and H5 Influenza Virus Infection and Vaccination										
Associated Grant Nu	umbers:					,				
Non-NIH Funded										
Summary of Approv	ed Items:									
Propagation of H2N2		nfluenza	viru	s and subs	sequent asse	essment in	vivo			
vaccinated under FLI					•					
Requested Additions	s/Changes:									
 Addition of n 	ew in vivo study	7								
	•									
Function/Nature of R	ecombinant Ger	nes to be	Expr	essed:						
⊠ N/A □ Oncogene			-		al 🗆 Signal	ling □ An	timicrobial			
☐ Immunomodulatory					_	-				
Species of Recombina	ant Genes to be	Expresse	ed:							
⊠ N/A □ Human □				□ Viral □	☐ Other					
Risk Assessment Dis	cussion:		Fa	acilities, P	Procedures,	and Safet	y Practices			
⊠ Yes □ No				eviewed (
			\boxtimes	Yes	□ No					
Discussion/Required	Modifications	:								
• Administrativ										
	anguage for temp	noral sna	cino	for propo	sed study					
	dures for bite glo			ioi piopo	sea staay					
o paule proceed	iures for one gre	ove remo	vai							
PI/Supervisor Training (Y/N): Handler Training (Y/N):										
	g (1/11).			⊠ Yes	□ No	1/1//				
Motion:				1						
Approved with	Fo	r:	A	gainst:	Abstain:	Recuse:	Not			
Administrative Revis				0	1	0	Present:			
				-	-	-	0			